Effects of Citicoline as an Adjunct Treatment for Alzheimer's Disease: A Systematic Review.

Author: AnlacanVeeda Michelle M, EspirituAdrian I, PiamonteBernadeth Lyn C

Paper Details 
Original Abstract of the Article :
BACKGROUND: A critical strategy in the management of Alzheimer's disease (AD) is optimizing the effects of currently available pharmacologic therapies such as citicoline (CC). OBJECTIVE: The purpose of this study was to determine the effects of CC as adjunct therapy to cholinesterase inhibitors (AC...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.3233/JAD-200378

データ提供:米国国立医学図書館(NLM)

Citicoline for Alzheimer's Disease: Adjunct Therapy Insights

Alzheimer's disease (AD), a progressive neurodegenerative disorder, is a growing public health concern. Imagine a traveler, slowly losing their way in a vast and unfamiliar desert, their memories fading with each passing day. This systematic review explores the effectiveness of citicoline (CC) as an adjunct therapy for AD, examining its potential benefits when used in combination with cholinesterase inhibitors (AChEIs). The authors identified two retrospective cohort studies that evaluated the effects of CC on cognitive function, mood, and behavioral symptoms in patients with AD. Their findings suggest that CC, when used in conjunction with AChEIs, may be well-tolerated and show improvement in cognitive function, mood, and behavioral symptoms compared to AChEI monotherapy. These results highlight the potential of CC as a valuable adjunct therapy for managing AD.

Harnessing the Potential of Adjunct Therapy

This systematic review underscores the potential of CC as an adjunct therapy for AD. The findings suggest that CC, when used in combination with AChEIs, may offer a multi-pronged approach to managing the cognitive, mood, and behavioral symptoms associated with AD. This research encourages further investigation into the effectiveness and safety of CC as a complementary therapy for AD, potentially leading to improved outcomes for patients.

Living with Alzheimer's: A Journey of Support and Hope

Alzheimer's disease is a challenging condition for both patients and their families. This systematic review offers a ray of hope, highlighting the potential of CC to improve cognitive function and overall well-being. It encourages healthcare professionals to consider CC as a valuable adjunct therapy for AD, providing a more comprehensive approach to managing this complex disease.

Dr.Camel's Conclusion

The desert of Alzheimer's disease can be a daunting and disorienting landscape. This systematic review offers a potential oasis of hope, exploring the benefits of citicoline as an adjunct therapy for managing this challenging condition. By harnessing the power of complementary therapies like CC, we can provide greater support and improve outcomes for those living with Alzheimer's disease.

Date :
  1. Date Completed 2021-05-07
  2. Date Revised 2021-05-07
Further Info :

Pubmed ID

32538854

DOI: Digital Object Identifier

10.3233/JAD-200378

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.